Doxorubicin and BAY 12-9566 for the treatment of osteosarcoma in dogs: a randomized, double-blind, placebo-controlled study.

Background: This study was designed to assess the efficacy of a matrix metalloproteinase inhibitor in prolonging posttreatment survival for dogs with appendicular osteosarcoma after treatment with amputation and doxorubicin chemotherapy.

Hypothesis: Survival will be prolonged in dogs receiving BAY 12-9566.

Animals: The study included 303 dogs with appendicular osteosarcoma.